Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India Considers Easing Price-Hike Limits On Drugs

This article was originally published in PharmAsia News

Executive Summary

Indian authorities are considering an increase in the price caps on 70 scheduled drugs as drug makers plead for relief from their rising manufacturing expenses, such as the high price of ingredients from China. Also under consideration by the chemicals ministry and the drug price regulator is suspension of the annual 10 percent limit on price increases for drugs not under direct control. The plan includes revising the prices of several bulk drugs. Of the 70 scheduled drugs, 30 are imports by multinational drug makers. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069125

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel